Edinburgh, Scotland, 28th February, 2019 – AdoRx Therapeutics, a UK based drug discovery company, today announced that it has entered into a strategic collaboration with
New designation now includes all PNH patients CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development
CRESTWOOD, Ky., and WALTHAM, Mass., – Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases
Represents New Hope for Repairing Challenging Bone Fractures Aberdeen, UK, January 31, 2019– SIRAKOSS Ltd, a developer of nanosynthetic bone graft substitutes to transform the
We are pleased to welcome Terri Burke to the Epidarex team. Terri joins the Epidarex transatlantic team as a Venture Partner and will focus on
The following article was published in The Times on December 26, 2018 Mention the word “charity” to most people and they’ll think of the grey-haired
New investors Alsa Holdings and UCL Technology Fund join Epidarex Capital Proceeds will allow IGEM to continue development of IgE therapeutic antibody portfolio and novel
Seasoned CEO with 30 years’ experience in the healthcare industry Edinburgh, United Kingdom, 8 November 2018 – Edinburgh Molecular Imaging (EM Imaging), the optical molecular
Roy Davis appointed as Non-Executive Chairman. Current Chair John Jeans to continue as Non-Executive Director Edinburgh Molecular Imaging Ltd (EM Imaging), the clinical phase biotechnology
Expansion in the US is consistent with NodThera’s strategy to access world class talent, foster collaborative relationships and develop deep insights into inflammasome biology to